UK Continuous, Integrated Biologics Manufacturing Project

英国连续、综合生物制剂制造项目

• 批准号: 102623
• 金额: $ 183.16万
• 依托单位: PALL EUROPE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102623
• 关键词: UK; Continuous; Integrated; Biologics; Manufacturing

As biopharma moves to the business mainstream, the industry will increasingly need to find new waysto maintain competitiveness by ensuring affordability, quality, and delivery performance. Continuousprocesses have been proposed as a solution as they are scalable, offer higher productivity with reducedrunning times and materials usage, and require smaller footprint and less capital intense facilities. Theproject brings together five leading biopharmaceutical companies with UK Operations, processtechnology suppliers and a Catapult centre to develop an automated continuous biologics purificationunit for more efficient manufacture of a wide range of biologic drugs. The new unit will consist ofintegrated, multiple operations running concurrently.

随着生物制药走向商业主流，该行业将越来越需要找到新的方法，通过确保价格、质量和交付性能来保持竞争力。连续工艺被提出作为一种解决方案，因为它们具有可扩展性，可以通过减少生产时间和材料使用来提供更高的生产率，并且需要更小的占地面积和更少的资本密集型设施。该项目将五家领先的生物制药公司与英国运营、工艺技术供应商和弹射器中心联合起来，开发一种自动化的连续生物制剂纯化装置，以更有效地生产各种生物药物。新单位将包括多个同时运行的集成操作。